Cargando…

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?

Detalles Bibliográficos
Autores principales:	Park, Cheol-Kyu, Oh, In-Jae, Kim, Young-Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799057/ https://www.ncbi.nlm.nih.gov/pubmed/35116765 http://dx.doi.org/10.21037/tcr.2019.03.22

Ejemplares similares

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

SCLC extensive disease – treatment guidance by extent or/and biology of response?
por: Eckert, Franziska, et al.
Publicado: (2008)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)
por: Xie, Tongji, et al.
Publicado: (2020)

De Novo KRAS G12C–Mutant SCLC: A Case Report
por: Balbach, Meridith L., et al.
Publicado: (2022)

Small Cell Lung Cancer (SCLC) Presenting as Acute Pancreatitis: The Role of Hypercalcemia
por: Tan, Jessica, et al.
Publicado: (2012)

Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes
por: Bebber, Christina M., et al.
Publicado: (2021)

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
por: Oronsky, Bryan, et al.
Publicado: (2022)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy
por: Zeng, Jiao, et al.
Publicado: (2023)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
por: Ito, Takanori, et al.
Publicado: (2023)

In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”
por: Moore, Margaret, et al.
Publicado: (2022)

Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC).
por: Jørgensen, L. G., et al.
Publicado: (1994)

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
por: Men, Yu, et al.
Publicado: (2017)

SCLC-J1, a novel small cell lung cancer cell line
por: Ohara, Kazuo, et al.
Publicado: (2021)

Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)
por: Ding, Xiao-Long, et al.
Publicado: (2022)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

Impact of Socioeconomic Factors on Overall Survival in SCLC
por: Roof, Logan, et al.
Publicado: (2022)

Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice
por: Richards, Donald, et al.
Publicado: (2015)

Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models
por: Salgia, Ravi, et al.
Publicado: (2018)

Tracheal polypoid combined small cell lung cancer (C‐SCLC): A case report
por: Testori, Alberto, et al.
Publicado: (2021)

Circulating progastrin-releasing peptide in the diagnosis of Small Cell Lung Cancer (SCLC) and in therapeutic monitoring
por: Barchiesi, Vittoria, et al.
Publicado: (2021)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
por: Kunimasa, Kei, et al.
Publicado: (2022)

Author Reply: In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”
por: Balbach, Meridith L., et al.
Publicado: (2022)

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
por: Domvri, Kalliopi, et al.
Publicado: (2015)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

Promising Role of Circulating Tumor Cells in the Management of SCLC
por: De Luca, Antonella, et al.
Publicado: (2021)

Correction to: Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Organoids as a Systems Platform for SCLC Brain Metastasis
por: Quaranta, Vito, et al.
Publicado: (2022)

Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting
por: Lekic, Mirko, et al.
Publicado: (2012)

Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC)
por: Deneka, Alexander Y., et al.
Publicado: (2019)

Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients
por: von Eiff, Damian, et al.
Publicado: (2020)

Non-neuroendocrine differentiation generates a ferroptosis-prone lipidome in small cell lung cancer (SCLC)
por: Bebber, Christina M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_67s61jll5797536pje14kfvfsd